• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

γδ T细胞介导小鼠接种昆虫源性基孔肯雅热疫苗后的保护性免疫。

γδ T Cells Mediate Protective Immunity Following Vaccination with an Insect-Based Chikungunya Fever Vaccine in Mice.

作者信息

Rodriguez Leslie, Adam Awadalkareem, Luo Huanle, Osman Samantha R, Plante Kenneth, Rossi Shannan L, Weaver Scott C, Wang Tian

机构信息

Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.

Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX 77555, USA.

出版信息

Pathogens. 2025 Aug 30;14(9):863. doi: 10.3390/pathogens14090863.

DOI:10.3390/pathogens14090863
PMID:41011763
Abstract

Eilat (EILV)/chikungunya virus (CHIKV) is a chimeric virus that contains the nonstructural proteins and cis-acting sequences of EILV and the structural proteins of CHIKV. EILV/CHIKV vaccination is known to protect with a single dose against wild-type (WT) CHIKV challenge in mice and non-human primates. The underlying immune mechanism of the vaccine-induced host protection remains unknown. γδ T cells react to WT CHIKV infection by controlling the virus-induced tissue inflammation and damage. Here, we found that γδ T cells contribute to EILV/CHIKV-induced host protection against WT CHIKV infection. TCRδ mice, which are deficient of γδ T cells, had impaired CHIKV-specific CD8 T cell responses, antibody production and memory B cell responses following vaccination. Both antibody and CD8 T cells of EILV/CHIKV-vaccinated mice were required for protection type I interferon receptor deficient mice from lethal WT CHIKV infection. Moreover, γδ T cells expanded quickly in response to EILV/CHIKV vaccination. TCRδ mice, had lower levels of innate immune cytokines and impaired activation of antigen presenting cell (APCs). Overall, γδ T cells contribute to EILV/CHIKV-induced host protection by promoting APC maturation, T cell priming and the induction of humoral immune responses upon EILV/CHIKV vaccination.

摘要

埃拉特病毒(EILV)/基孔肯雅病毒(CHIKV)是一种嵌合病毒,它包含埃拉特病毒的非结构蛋白和顺式作用序列以及基孔肯雅病毒的结构蛋白。已知埃拉特病毒/基孔肯雅病毒疫苗接种单剂量就能保护小鼠和非人灵长类动物免受野生型(WT)基孔肯雅病毒攻击。疫苗诱导宿主产生保护作用的潜在免疫机制尚不清楚。γδT细胞通过控制病毒诱导的组织炎症和损伤来应对野生型基孔肯雅病毒感染。在此,我们发现γδT细胞有助于埃拉特病毒/基孔肯雅病毒诱导宿主抵御野生型基孔肯雅病毒感染。缺乏γδT细胞的TCRδ小鼠在接种疫苗后,其基孔肯雅病毒特异性CD8 T细胞反应、抗体产生和记忆B细胞反应均受损。埃拉特病毒/基孔肯雅病毒疫苗接种小鼠的抗体和CD8 T细胞对于保护I型干扰素受体缺陷小鼠免受致死性野生型基孔肯雅病毒感染都是必需的。此外,γδT细胞对埃拉特病毒/基孔肯雅病毒疫苗接种反应迅速扩增。TCRδ小鼠的固有免疫细胞因子水平较低,抗原呈递细胞(APC)的激活受损。总体而言,γδT细胞通过促进抗原呈递细胞成熟、T细胞启动以及在埃拉特病毒/基孔肯雅病毒疫苗接种时诱导体液免疫反应,来促成埃拉特病毒/基孔肯雅病毒诱导的宿主保护作用。

相似文献

1
γδ T Cells Mediate Protective Immunity Following Vaccination with an Insect-Based Chikungunya Fever Vaccine in Mice.γδ T细胞介导小鼠接种昆虫源性基孔肯雅热疫苗后的保护性免疫。
Pathogens. 2025 Aug 30;14(9):863. doi: 10.3390/pathogens14090863.
2
Humoral and cellular immune response to a single dose of a novel bivalent recombinant adenovirus-vector vaccine against West Nile virus and chikungunya virus in mice.小鼠对单剂量新型二价重组腺病毒载体西尼罗河病毒和基孔肯雅病毒疫苗的体液免疫和细胞免疫反应
Virol J. 2025 Jul 25;22(1):256. doi: 10.1186/s12985-025-02878-5.
3
Optimized production and immunogenicity of an insect virus-based chikungunya virus candidate vaccine in cell culture and animal models.优化细胞培养和动物模型中基于昆虫病毒的基孔肯雅病毒候选疫苗的生产和免疫原性。
Emerg Microbes Infect. 2021 Dec;10(1):305-316. doi: 10.1080/22221751.2021.1886598.
4
A chikungunya fever vaccine utilizing an insect-specific virus platform.一种利用昆虫特异性病毒平台的基孔肯雅热疫苗。
Nat Med. 2017 Feb;23(2):192-199. doi: 10.1038/nm.4253. Epub 2016 Dec 19.
5
DDO-adjuvanted influenza A virus nucleoprotein mRNA vaccine induces robust humoral and cellular type 1 immune responses and protects mice from challenge.含双脱氧鸟苷佐剂的甲型流感病毒核蛋白mRNA疫苗可诱导强烈的体液免疫和1型细胞免疫反应,并保护小鼠免受攻击。
mBio. 2025 Feb 5;16(2):e0358924. doi: 10.1128/mbio.03589-24. Epub 2024 Dec 18.
6
Chikungunya virus E2 B domain nanoparticle immunogen elicits homotypic neutralizing antibody in mice.基孔肯雅病毒E2 B结构域纳米颗粒免疫原在小鼠体内引发同型中和抗体。
Vaccine. 2024 Dec 2;42(26):126405. doi: 10.1016/j.vaccine.2024.126405. Epub 2024 Oct 15.
7
A safe insect-based chikungunya fever vaccine affords rapid and durable protection in cynomolgus macaques.一种安全的基于昆虫的基孔肯雅热疫苗在食蟹猕猴中提供快速且持久的保护。
NPJ Vaccines. 2024 Dec 19;9(1):251. doi: 10.1038/s41541-024-01047-z.
8
Vaccine-Induced Skewing of T Cell Responses Protects Against Chikungunya Virus Disease.疫苗诱导的 T 细胞反应偏倚可预防基孔肯雅热病毒病。
Front Immunol. 2019 Oct 31;10:2563. doi: 10.3389/fimmu.2019.02563. eCollection 2019.
9
Lipid nanoparticles as adjuvant of norovirus VLP vaccine augment cellular and humoral immune responses in a TLR9- and type I IFN-dependent pathway.脂质纳米颗粒作为诺如病毒VLP疫苗的佐剂,通过TLR9和I型干扰素依赖性途径增强细胞免疫和体液免疫反应。
J Virol. 2024 Dec 17;98(12):e0169924. doi: 10.1128/jvi.01699-24. Epub 2024 Nov 4.
10
Inactivated Viral Vaccine BBV87 Protects Against Chikungunya Virus Challenge in a Non-Human Primate Model.灭活病毒疫苗BBV87在非人灵长类动物模型中可抵御基孔肯雅病毒攻击。
Viruses. 2025 Apr 10;17(4):550. doi: 10.3390/v17040550.

本文引用的文献

1
Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial.基孔肯雅病毒样颗粒疫苗在美国青少年和成年人中的安全性和免疫原性:一项3期随机双盲安慰剂对照试验。
Lancet. 2025 Apr 19;405(10487):1343-1352. doi: 10.1016/S0140-6736(25)00345-9. Epub 2025 Mar 27.
2
A safe insect-based chikungunya fever vaccine affords rapid and durable protection in cynomolgus macaques.一种安全的基于昆虫的基孔肯雅热疫苗在食蟹猕猴中提供快速且持久的保护。
NPJ Vaccines. 2024 Dec 19;9(1):251. doi: 10.1038/s41541-024-01047-z.
3
Pellino-1, a therapeutic target for control of SARS-CoV-2 infection and disease severity.
佩利诺-1,一种控制新型冠状病毒感染和疾病严重程度的治疗靶点。
Antiviral Res. 2025 Jan;233:106059. doi: 10.1016/j.antiviral.2024.106059. Epub 2024 Dec 15.
4
A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults†.一项随机、双盲3期研究,旨在证明减毒活基孔肯雅病毒候选疫苗VLA1553在健康成年人中的批次间一致性,并确认其免疫原性和安全性† 。
J Travel Med. 2024 Mar 1;31(2). doi: 10.1093/jtm/taad156.
5
Prime-boost with Chikungunya virus E2 envelope protein combined with Poly (I:C) induces specific humoral and cellular immune responses.用基孔肯雅病毒E2包膜蛋白联合聚肌胞苷酸进行初免-加强免疫可诱导特异性体液免疫和细胞免疫反应。
Curr Res Immunol. 2021 Mar 17;2:23-31. doi: 10.1016/j.crimmu.2021.03.001. eCollection 2021.
6
Emerging Chikungunya Virus Variants at the E1-E1 Interglycoprotein Spike Interface Impact Virus Attachment and Inflammation.新兴基孔肯雅病毒变异株在 E1-E1 糖蛋白刺突界面影响病毒附着和炎症反应。
J Virol. 2022 Feb 23;96(4):e0158621. doi: 10.1128/JVI.01586-21. Epub 2021 Dec 22.
7
Optimized production and immunogenicity of an insect virus-based chikungunya virus candidate vaccine in cell culture and animal models.优化细胞培养和动物模型中基于昆虫病毒的基孔肯雅病毒候选疫苗的生产和免疫原性。
Emerg Microbes Infect. 2021 Dec;10(1):305-316. doi: 10.1080/22221751.2021.1886598.
8
Chikungunya Virus Evades Antiviral CD8 T Cell Responses To Establish Persistent Infection in Joint-Associated Tissues.基孔肯雅病毒逃避抗病毒 CD8 T 细胞应答,从而在关节相关组织中建立持续性感染。
J Virol. 2020 Apr 16;94(9). doi: 10.1128/JVI.02036-19.
9
Vaccine-Induced Skewing of T Cell Responses Protects Against Chikungunya Virus Disease.疫苗诱导的 T 细胞反应偏倚可预防基孔肯雅热病毒病。
Front Immunol. 2019 Oct 31;10:2563. doi: 10.3389/fimmu.2019.02563. eCollection 2019.
10
Multiplexed FluoroSpot for the Analysis of Dengue Virus- and Zika Virus-Specific and Cross-Reactive Memory B Cells.多重荧光酶联免疫斑点技术分析登革病毒和寨卡病毒特异性及交叉反应性记忆 B 细胞
J Immunol. 2018 Dec 15;201(12):3804-3814. doi: 10.4049/jimmunol.1800892. Epub 2018 Nov 9.